000092765303/312024Q3false38835737000009276532023-04-012023-12-310000927653us-gaap:CommonStockMember2023-04-012023-12-310000927653mck:A1500NotesDue2025Member2023-04-012023-12-310000927653mck:A1625NotesDue2026Member2023-04-012023-12-310000927653mck:A3125NotesDue2029Member2023-04-012023-12-3100009276532023-12-31xbrli:shares00009276532023-10-012023-12-31iso4217:USD00009276532022-10-012022-12-3100009276532022-04-012022-12-31iso4217:USDxbrli:shares00009276532023-03-310000927653us-gaap:CommonStockMember2023-09-300000927653us-gaap:AdditionalPaidInCapitalMember2023-09-300000927653us-gaap:RetainedEarningsMember2023-09-300000927653us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300000927653us-gaap:TreasuryStockCommonMember2023-09-300000927653us-gaap:NoncontrollingInterestMember2023-09-3000009276532023-09-300000927653us-gaap:CommonStockMember2023-10-012023-12-310000927653us-gaap:AdditionalPaidInCapitalMember2023-10-012023-12-310000927653us-gaap:TreasuryStockCommonMember2023-10-012023-12-310000927653us-gaap:RetainedEarningsMember2023-10-012023-12-310000927653us-gaap:NoncontrollingInterestMember2023-10-012023-12-310000927653us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-10-012023-12-310000927653us-gaap:CommonStockMember2023-12-310000927653us-gaap:AdditionalPaidInCapitalMember2023-12-310000927653us-gaap:RetainedEarningsMember2023-12-310000927653us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000927653us-gaap:TreasuryStockCommonMember2023-12-310000927653us-gaap:NoncontrollingInterestMember2023-12-310000927653us-gaap:CommonStockMember2022-09-300000927653us-gaap:AdditionalPaidInCapitalMember2022-09-300000927653us-gaap:RetainedEarningsMember2022-09-300000927653us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300000927653us-gaap:TreasuryStockCommonMember2022-09-300000927653us-gaap:NoncontrollingInterestMember2022-09-3000009276532022-09-300000927653us-gaap:AdditionalPaidInCapitalMember2022-10-012022-12-310000927653us-gaap:TreasuryStockCommonMember2022-10-012022-12-310000927653us-gaap:RetainedEarningsMember2022-10-012022-12-310000927653us-gaap:NoncontrollingInterestMember2022-10-012022-12-310000927653us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-10-012022-12-310000927653us-gaap:CommonStockMember2022-12-310000927653us-gaap:AdditionalPaidInCapitalMember2022-12-310000927653us-gaap:RetainedEarningsMember2022-12-310000927653us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000927653us-gaap:TreasuryStockCommonMember2022-12-310000927653us-gaap:NoncontrollingInterestMember2022-12-3100009276532022-12-310000927653us-gaap:CommonStockMember2023-03-310000927653us-gaap:AdditionalPaidInCapitalMember2023-03-310000927653us-gaap:RetainedEarningsMember2023-03-310000927653us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310000927653us-gaap:TreasuryStockCommonMember2023-03-310000927653us-gaap:NoncontrollingInterestMember2023-03-310000927653us-gaap:CommonStockMember2023-04-012023-12-310000927653us-gaap:AdditionalPaidInCapitalMember2023-04-012023-12-310000927653us-gaap:TreasuryStockCommonMember2023-04-012023-12-310000927653us-gaap:RetainedEarningsMember2023-04-012023-12-310000927653us-gaap:NoncontrollingInterestMember2023-04-012023-12-310000927653us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-12-310000927653us-gaap:CommonStockMember2022-03-310000927653us-gaap:AdditionalPaidInCapitalMember2022-03-310000927653us-gaap:RetainedEarningsMember2022-03-310000927653us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310000927653us-gaap:TreasuryStockCommonMember2022-03-310000927653us-gaap:NoncontrollingInterestMember2022-03-3100009276532022-03-310000927653us-gaap:CommonStockMember2022-04-012022-12-310000927653us-gaap:AdditionalPaidInCapitalMember2022-04-012022-12-310000927653us-gaap:TreasuryStockCommonMember2022-04-012022-12-310000927653us-gaap:RetainedEarningsMember2022-04-012022-12-310000927653us-gaap:NoncontrollingInterestMember2022-04-012022-12-310000927653us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-12-31mck:segment0000927653mck:RxTsSegmentMembermck:RxSavingsSolutionsLLCMember2022-11-01xbrli:pure0000927653mck:RxTsSegmentMembermck:RxSavingsSolutionsLLCMember2022-11-012022-11-010000927653mck:RxTsSegmentMembersrt:MaximumMembermck:RxSavingsSolutionsLLCMember2022-11-010000927653mck:RxSavingsSolutionsLLCMember2023-10-012023-12-310000927653mck:RxSavingsSolutionsLLCMember2023-04-012023-12-310000927653mck:RxTsSegmentMembermck:RxSavingsSolutionsLLCMember2023-12-310000927653mck:RxTsSegmentMembermck:RxSavingsSolutionsLLCMember2023-03-310000927653mck:USPharmaceuticalSegmentMembermck:SCRIOncologyLLCMember2022-10-310000927653mck:USPharmaceuticalSegmentMembermck:SCRIOncologyLLCMember2022-10-312022-10-310000927653mck:USPharmaceuticalSegmentMembermck:SarahCannonResearchInstituteMembermck:SCRIOncologyLLCMember2022-10-310000927653mck:McKessonUSOncologyResearchMembermck:USPharmaceuticalSegmentMembermck:SCRIOncologyLLCMember2022-10-310000927653us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMembermck:EUBusinessesDisposalGroupMember2022-10-312022-10-310000927653us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMembermck:EUBusinessesDisposalGroupMember2022-10-310000927653us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMembermck:EUBusinessesDisposalGroupMember2022-10-012022-12-310000927653us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMembermck:EUBusinessesDisposalGroupMember2022-04-012022-12-310000927653us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMembermck:UKBusinessesDisposalGroupMember2022-04-06iso4217:GBP0000927653us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMembermck:InternationalSegmentMember2022-04-060000927653mck:AureliusElephantLimitedMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMembermck:InternationalSegmentMember2022-04-062022-04-060000927653us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMembermck:UKBusinessesDisposalGroupMember2022-04-062022-04-060000927653mck:StrategicGrowthInitiativePlanOperationalEfficienciesAndCostOptimizationMember2023-03-310000927653mck:StrategicGrowthInitiativePlanOperationalEfficienciesAndCostOptimizationMember2023-01-012023-12-310000927653mck:StrategicGrowthInitiativePlanOperationalEfficienciesAndCostOptimizationMember2023-10-012023-12-310000927653mck:StrategicGrowthInitiativePlanOperationalEfficienciesAndCostOptimizationMember2023-04-012023-12-310000927653us-gaap:OperatingSegmentsMembermck:USPharmaceuticalSegmentMember2023-10-012023-12-310000927653us-gaap:OperatingSegmentsMembermck:PrescriptionTechnologySolutionsSegmentMember2023-10-012023-12-310000927653us-gaap:OperatingSegmentsMembermck:MedicalSurgicalSolutionsSegmentMember2023-10-012023-12-310000927653us-gaap:OperatingSegmentsMembermck:InternationalSegmentMember2023-10-012023-12-310000927653us-gaap:CorporateNonSegmentMember2023-10-012023-12-310000927653us-gaap:OperatingSegmentsMembermck:USPharmaceuticalSegmentMember2022-10-012022-12-310000927653us-gaap:OperatingSegmentsMembermck:PrescriptionTechnologySolutionsSegmentMember2022-10-012022-12-310000927653us-gaap:OperatingSegmentsMembermck:MedicalSurgicalSolutionsSegmentMember2022-10-012022-12-310000927653us-gaap:OperatingSegmentsMembermck:InternationalSegmentMember2022-10-012022-12-310000927653us-gaap:CorporateNonSegmentMember2022-10-012022-12-310000927653us-gaap:OperatingSegmentsMembermck:USPharmaceuticalSegmentMember2023-04-012023-12-310000927653us-gaap:OperatingSegmentsMembermck:PrescriptionTechnologySolutionsSegmentMember2023-04-012023-12-310000927653us-gaap:OperatingSegmentsMembermck:MedicalSurgicalSolutionsSegmentMember2023-04-012023-12-310000927653us-gaap:OperatingSegmentsMembermck:InternationalSegmentMember2023-04-012023-12-310000927653us-gaap:CorporateNonSegmentMember2023-04-012023-12-310000927653us-gaap:OperatingSegmentsMembermck:USPharmaceuticalSegmentMember2022-04-012022-12-310000927653us-gaap:OperatingSegmentsMembermck:PrescriptionTechnologySolutionsSegmentMember2022-04-012022-12-310000927653us-gaap:OperatingSegmentsMembermck:MedicalSurgicalSolutionsSegmentMember2022-04-012022-12-310000927653us-gaap:OperatingSegmentsMembermck:InternationalSegmentMember2022-04-012022-12-310000927653us-gaap:CorporateNonSegmentMember2022-04-012022-12-310000927653us-gaap:OperatingSegmentsMembermck:USPharmaceuticalSegmentMember2023-03-310000927653us-gaap:OperatingSegmentsMembermck:PrescriptionTechnologySolutionsSegmentMember2023-03-310000927653us-gaap:OperatingSegmentsMembermck:MedicalSurgicalSolutionsSegmentMember2023-03-310000927653us-gaap:OperatingSegmentsMembermck:InternationalSegmentMember2023-03-310000927653us-gaap:CorporateNonSegmentMember2023-03-310000927653us-gaap:OperatingSegmentsMembermck:USPharmaceuticalSegmentMember2023-12-310000927653us-gaap:OperatingSegmentsMembermck:PrescriptionTechnologySolutionsSegmentMember2023-12-310000927653us-gaap:OperatingSegmentsMembermck:MedicalSurgicalSolutionsSegmentMember2023-12-310000927653us-gaap:OperatingSegmentsMembermck:InternationalSegmentMember2023-12-310000927653us-gaap:CorporateNonSegmentMember2023-12-310000927653us-gaap:AccruedLiabilitiesMember2023-03-310000927653us-gaap:OtherNoncurrentLiabilitiesMember2023-03-310000927653us-gaap:AccruedLiabilitiesMember2023-12-310000927653us-gaap:OtherNoncurrentLiabilitiesMember2023-12-310000927653srt:MinimumMember2023-12-310000927653srt:MaximumMember2023-12-310000927653us-gaap:EmployeeStockOptionMember2023-10-012023-12-310000927653us-gaap:EmployeeStockOptionMember2022-10-012022-12-310000927653us-gaap:EmployeeStockOptionMember2023-04-012023-12-310000927653us-gaap:EmployeeStockOptionMember2022-04-012022-12-310000927653us-gaap:RestrictedStockUnitsRSUMember2023-10-012023-12-310000927653us-gaap:RestrictedStockUnitsRSUMember2022-10-012022-12-310000927653us-gaap:RestrictedStockUnitsRSUMember2023-04-012023-12-310000927653us-gaap:RestrictedStockUnitsRSUMember2022-04-012022-12-310000927653mck:USPharmaceuticalSegmentMember2023-03-310000927653mck:PrescriptionTechnologySolutionsSegmentMember2023-03-310000927653mck:MedicalSurgicalSolutionsSegmentMember2023-03-310000927653mck:InternationalSegmentMember2023-03-310000927653mck:USPharmaceuticalSegmentMember2023-10-012023-12-310000927653mck:PrescriptionTechnologySolutionsSegmentMember2023-10-012023-12-310000927653mck:MedicalSurgicalSolutionsSegmentMember2023-10-012023-12-310000927653mck:InternationalSegmentMember2023-10-012023-12-310000927653mck:USPharmaceuticalSegmentMember2023-04-012023-12-310000927653mck:PrescriptionTechnologySolutionsSegmentMember2023-04-012023-12-310000927653mck:MedicalSurgicalSolutionsSegmentMember2023-04-012023-12-310000927653mck:InternationalSegmentMember2023-04-012023-12-310000927653mck:USPharmaceuticalSegmentMember2023-12-310000927653mck:PrescriptionTechnologySolutionsSegmentMember2023-12-310000927653mck:MedicalSurgicalSolutionsSegmentMember2023-12-310000927653mck:InternationalSegmentMember2023-12-310000927653us-gaap:CustomerRelationshipsMember2023-12-310000927653us-gaap:CustomerRelationshipsMember2023-03-310000927653us-gaap:ServiceAgreementsMember2023-12-310000927653us-gaap:ServiceAgreementsMember2023-03-310000927653us-gaap:TrademarksAndTradeNamesMember2023-12-310000927653us-gaap:TrademarksAndTradeNamesMember2023-03-310000927653us-gaap:TechnologyBasedIntangibleAssetsMember2023-12-310000927653us-gaap:TechnologyBasedIntangibleAssetsMember2023-03-310000927653us-gaap:OtherIntangibleAssetsMember2023-12-310000927653us-gaap:OtherIntangibleAssetsMember2023-03-310000927653mck:A380NotesDueMarch152024Memberus-gaap:LoansPayableMember2023-12-310000927653mck:A380NotesDueMarch152024Memberus-gaap:LoansPayableMember2023-03-310000927653mck:A090NotesDueDecember32025Memberus-gaap:LoansPayableMember2023-12-310000927653mck:A090NotesDueDecember32025Memberus-gaap:LoansPayableMember2023-03-310000927653mck:A525NotesDueFebruary152026Memberus-gaap:LoansPayableMember2023-12-310000927653mck:A525NotesDueFebruary152026Memberus-gaap:LoansPayableMember2023-03-310000927653mck:A130NotesDueAugust152026Memberus-gaap:LoansPayableMember2023-12-310000927653mck:A130NotesDueAugust152026Memberus-gaap:LoansPayableMember2023-03-310000927653mck:A765DebenturesDueMarch12027Memberus-gaap:LoansPayableMember2023-12-310000927653mck:A765DebenturesDueMarch12027Memberus-gaap:LoansPayableMember2023-03-310000927653mck:A395NotesDueFebruary162028Memberus-gaap:LoansPayableMember2023-12-310000927653mck:A395NotesDueFebruary162028Memberus-gaap:LoansPayableMember2023-03-310000927653us-gaap:LoansPayableMembermck:A490NotesDueJuly152028Member2023-12-310000927653us-gaap:LoansPayableMembermck:A490NotesDueJuly152028Member2023-03-310000927653us-gaap:LoansPayableMembermck:A475NotesDueMay302029Member2023-12-310000927653us-gaap:LoansPayableMembermck:A475NotesDueMay302029Member2023-03-310000927653mck:A510NotesDueJuly152033Memberus-gaap:LoansPayableMember2023-12-310000927653mck:A510NotesDueJuly152033Memberus-gaap:LoansPayableMember2023-03-310000927653mck:A600NotesDueMarch12041Memberus-gaap:LoansPayableMember2023-12-310000927653mck:A600NotesDueMarch12041Memberus-gaap:LoansPayableMember2023-03-310000927653us-gaap:LoansPayableMembermck:A488NotesDueMarch152044Member2023-12-310000927653us-gaap:LoansPayableMembermck:A488NotesDueMarch152044Member2023-03-310000927653mck:A150EuroNotesDueNovember172025Memberus-gaap:LoansPayableMember2023-12-310000927653mck:A150EuroNotesDueNovember172025Memberus-gaap:LoansPayableMember2023-03-310000927653mck:A163EuroNotesDueOctober302026Memberus-gaap:LoansPayableMember2023-12-310000927653mck:A163EuroNotesDueOctober302026Memberus-gaap:LoansPayableMember2023-03-310000927653mck:A313SterlingNotesDueFebruary172029Memberus-gaap:LoansPayableMember2023-12-310000927653mck:A313SterlingNotesDueFebruary172029Memberus-gaap:LoansPayableMember2023-03-310000927653mck:LeaseAndOtherObligationsMember2023-12-310000927653mck:LeaseAndOtherObligationsMember2023-03-310000927653us-gaap:LoansPayableMembermck:A490NotesDueJuly152028Member2023-06-150000927653mck:A510NotesDueJuly152033Memberus-gaap:LoansPayableMember2023-06-150000927653us-gaap:LoansPayableMembermck:A490NotesDueJuly152028Member2023-06-152023-06-150000927653mck:A510NotesDueJuly152033Memberus-gaap:LoansPayableMember2023-06-152023-06-150000927653mck:A380NotesDueMarch152024Memberus-gaap:LoansPayableMember2023-06-150000927653srt:MinimumMemberus-gaap:LoansPayableMember2023-06-152023-06-150000927653srt:MaximumMemberus-gaap:LoansPayableMember2023-06-152023-06-150000927653us-gaap:LoansPayableMember2023-06-152023-06-150000927653mck:A380NotesDueMarch152024Memberus-gaap:LoansPayableMember2023-06-162023-06-160000927653mck:A380NotesDueMarch152024Memberus-gaap:LoansPayableMember2023-06-160000927653mck:A380NotesDueMarch152024Memberus-gaap:LoansPayableMember2023-04-012023-12-310000927653us-gaap:UnsecuredDebtMemberus-gaap:RevolvingCreditFacilityMembermck:SeniorUnsecuredCreditFacilityThe2022CreditFacilityMember2022-11-070000927653us-gaap:UnsecuredDebtMembermck:SeniorUnsecuredCreditFacilityThe2022CreditFacilityCanadianDollarBritishPoundSterlingAndEurosSublimitMemberus-gaap:RevolvingCreditFacilityMember2022-11-070000927653mck:SeniorUnsecuredCreditFacilitythe2020CreditFacilityMemberus-gaap:UnsecuredDebtMemberus-gaap:RevolvingCreditFacilityMember2019-09-250000927653mck:SeniorUnsecuredCreditFacilitythe2020CreditFacilityMemberus-gaap:UnsecuredDebtMemberus-gaap:RevolvingCreditFacilityMember2019-09-252019-09-250000927653mck:SeniorUnsecuredCreditFacilitythe2020CreditFacilityCanadianDollarBritishPoundSterlingandEurosSublimitMemberus-gaap:UnsecuredDebtMemberus-gaap:RevolvingCreditFacilityMember2022-04-012022-12-310000927653mck:SeniorUnsecuredCreditFacilitythe2020CreditFacilityCanadianDollarBritishPoundSterlingandEurosSublimitMemberus-gaap:UnsecuredDebtMemberus-gaap:RevolvingCreditFacilityMember2022-11-070000927653us-gaap:UnsecuredDebtMembermck:SeniorUnsecuredCreditFacilityThe2022CreditFacilityCanadianDollarBritishPoundSterlingAndEurosSublimitMemberus-gaap:RevolvingCreditFacilityMember2023-04-012023-12-310000927653us-gaap:UnsecuredDebtMembermck:SeniorUnsecuredCreditFacilityThe2022CreditFacilityCanadianDollarBritishPoundSterlingAndEurosSublimitMemberus-gaap:RevolvingCreditFacilityMember2023-12-310000927653us-gaap:CommercialPaperMember2023-12-310000927653us-gaap:CommercialPaperMember2023-04-012023-12-310000927653us-gaap:CommercialPaperMember2022-04-012022-12-310000927653us-gaap:CommercialPaperMember2023-03-310000927653us-gaap:CurrencySwapMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:EURus-gaap:FairValueHedgingMember2022-09-30iso4217:EUR0000927653us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMembermck:EuropeanBusinessesDisposalGroupMember2022-10-012022-12-310000927653us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMembermck:EuropeanBusinessesDisposalGroupMember2022-04-012022-12-310000927653mck:EuroDenominatedNotesMemberus-gaap:LoansPayableMember2022-12-310000927653us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMembermck:UKBusinessesDisposalGroupMember2022-04-012022-12-310000927653mck:BritishPoundSterlingDenominatedNotesMemberus-gaap:LoansPayableMember2022-12-310000927653us-gaap:DesignatedAsHedgingInstrumentMembermck:EuroDenominatedNotesMemberus-gaap:NetInvestmentHedgingMember2023-10-012023-12-310000927653us-gaap:DesignatedAsHedgingInstrumentMembermck:EuroDenominatedNotesMemberus-gaap:NetInvestmentHedgingMember2022-10-012022-12-310000927653us-gaap:DesignatedAsHedgingInstrumentMembermck:EuroDenominatedNotesMemberus-gaap:NetInvestmentHedgingMember2023-04-012023-12-310000927653us-gaap:DesignatedAsHedgingInstrumentMembermck:EuroDenominatedNotesMemberus-gaap:NetInvestmentHedgingMember2022-04-012022-12-310000927653us-gaap:DesignatedAsHedgingInstrumentMembercurrency:CADus-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMember2023-12-31iso4217:CAD0000927653us-gaap:DesignatedAsHedgingInstrumentMembercurrency:CADus-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMember2023-03-310000927653currency:GBPus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CurrencySwapMemberus-gaap:FairValueHedgingMember2023-12-310000927653currency:GBPus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CurrencySwapMemberus-gaap:FairValueHedgingMember2023-03-310000927653us-gaap:DesignatedAsHedgingInstrumentMembercurrency:EURus-gaap:CurrencySwapMemberus-gaap:FairValueHedgingMember2023-12-310000927653us-gaap:DesignatedAsHedgingInstrumentMembercurrency:EURus-gaap:CurrencySwapMemberus-gaap:FairValueHedgingMember2023-03-310000927653currency:USDus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMember2023-12-310000927653currency:USDus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMember2023-03-310000927653us-gaap:DesignatedAsHedgingInstrumentMembercurrency:CADus-gaap:CurrencySwapMemberus-gaap:CashFlowHedgingMember2023-12-310000927653us-gaap:DesignatedAsHedgingInstrumentMembercurrency:CADus-gaap:CurrencySwapMemberus-gaap:CashFlowHedgingMember2023-03-310000927653currency:GBPus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForwardContractsMemberus-gaap:CashFlowHedgingMember2023-12-310000927653currency:GBPus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForwardContractsMemberus-gaap:CashFlowHedgingMember2023-03-310000927653currency:USDmck:FixedInterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2023-12-310000927653currency:USDmck:FixedInterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2023-03-310000927653us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2022-04-012023-03-310000927653us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2023-04-012023-06-300000927653us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2023-06-150000927653us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2023-04-012023-12-310000927653us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMember2023-10-012023-12-310000927653us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMember2022-10-012022-12-310000927653us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMember2023-04-012023-12-310000927653us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMember2022-04-012022-12-310000927653us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CurrencySwapMemberus-gaap:CashFlowHedgingMember2023-10-012023-12-310000927653us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CurrencySwapMemberus-gaap:CashFlowHedgingMember2022-10-012022-12-310000927653us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CurrencySwapMemberus-gaap:CashFlowHedgingMember2023-04-012023-12-310000927653us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CurrencySwapMemberus-gaap:CashFlowHedgingMember2022-04-012022-12-310000927653us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForwardContractsMemberus-gaap:CashFlowHedgingMember2023-10-012023-12-310000927653us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForwardContractsMemberus-gaap:CashFlowHedgingMember2022-10-012022-12-310000927653us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForwardContractsMemberus-gaap:CashFlowHedgingMember2023-04-012023-12-310000927653us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForwardContractsMemberus-gaap:CashFlowHedgingMember2022-04-012022-12-310000927653mck:FixedInterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2023-10-012023-12-310000927653mck:FixedInterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2022-10-012022-12-310000927653mck:FixedInterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2023-04-012023-12-310000927653mck:FixedInterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2022-04-012022-12-310000927653mck:CurrentAssetLiabilityMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CurrencySwapMember2023-12-310000927653mck:CurrentAssetLiabilityMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CurrencySwapMember2023-03-310000927653us-gaap:DesignatedAsHedgingInstrumentMembermck:OtherNonCurrentAssetsAndLiabilitiesMemberus-gaap:CurrencySwapMember2023-12-310000927653us-gaap:DesignatedAsHedgingInstrumentMembermck:OtherNonCurrentAssetsAndLiabilitiesMemberus-gaap:CurrencySwapMember2023-03-310000927653us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMembermck:OtherNonCurrentAssetsAndLiabilitiesMember2023-12-310000927653us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMembermck:OtherNonCurrentAssetsAndLiabilitiesMember2023-03-310000927653us-gaap:DesignatedAsHedgingInstrumentMembermck:OtherAccruedLiabilitiesMemberus-gaap:ForwardContractsMember2023-12-310000927653us-gaap:DesignatedAsHedgingInstrumentMembermck:OtherAccruedLiabilitiesMemberus-gaap:ForwardContractsMember2023-03-310000927653us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForwardContractsMemberus-gaap:OtherNoncurrentLiabilitiesMember2023-12-310000927653us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForwardContractsMemberus-gaap:OtherNoncurrentLiabilitiesMember2023-03-310000927653us-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000927653us-gaap:DesignatedAsHedgingInstrumentMember2023-03-310000927653us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-12-310000927653us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-03-310000927653us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000927653us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000927653mck:NationalPrescriptionOpiateLitigationMember2023-12-31mck:distributormck:statemck:case0000927653mck:ThreeLargestUSPharmaceuticalDistributorsMembermck:NationalPrescriptionOpiateLitigationMember2023-04-012023-12-310000927653mck:StateOfAlabamaAndSubdivisionsMembermck:NationalPrescriptionOpiateLitigationMember2023-04-012023-12-310000927653mck:StateOfWestVirginiaAndSubdivisionsMembermck:NationalPrescriptionOpiateLitigationMembermck:ThreeNationalPharmaceuticalDistributorsMember2023-04-012023-12-310000927653mck:StateOfWestVirginiaAndSubdivisionsMemberus-gaap:SubsequentEventMembermck:NationalPrescriptionOpiateLitigationMembermck:ThreeNationalPharmaceuticalDistributorsMember2024-01-012024-01-31mck:subdivision0000927653mck:CherokeeNationMembermck:NationalPrescriptionOpiateLitigationMembermck:ThreeNationalPharmaceuticalDistributorsMember2023-04-012023-12-310000927653mck:NativeAmericanTribesOtherThanCherokeeNationMembermck:NationalPrescriptionOpiateLitigationMembermck:ThreeNationalPharmaceuticalDistributorsMember2023-04-012023-12-310000927653mck:NativeAmericanTribesOtherThanCherokeeNationMembermck:NationalPrescriptionOpiateLitigationMember2023-12-310000927653mck:NationalPrescriptionOpiateLitigationMember2023-12-310000927653mck:NationalPrescriptionOpiateLitigationMember2023-03-310000927653mck:NationalPrescriptionOpiateLitigationMember2023-04-012023-12-310000927653country:USmck:NationalPrescriptionOpiateLitigationMember2023-12-310000927653srt:ScenarioForecastMembermck:NationalPrescriptionOpiateLitigationMember2024-07-082024-07-08mck:plaintiff0000927653country:CAmck:NationalPrescriptionOpiateLitigationMember2023-12-310000927653mck:IndividualClaimantMembercountry:CAmck:NationalPrescriptionOpiateLitigationMember2023-12-310000927653mck:InsuranceCoverageLitigationMember2020-10-230000927653mck:InsuranceCoverageLitigationMember2022-04-05mck:policymck:vote00009276532023-07-012023-09-3000009276532023-07-012023-07-310000927653mck:OpenMarketShareRepurchaseTransactionsMember2023-10-012023-12-310000927653mck:OpenMarketShareRepurchaseTransactionsMember2023-12-310000927653mck:OpenMarketShareRepurchaseTransactionsMember2023-07-012023-09-300000927653mck:OpenMarketShareRepurchaseTransactionsMember2023-04-012023-06-300000927653mck:OpenMarketShareRepurchaseTransactionsMember2023-03-310000927653mck:OpenMarketShareRepurchaseTransactionsMember2022-10-012022-12-310000927653mck:OpenMarketShareRepurchaseTransactionsMember2022-07-012022-09-300000927653mck:OpenMarketShareRepurchaseTransactionsMember2022-04-012022-06-300000927653mck:AcceleratedShareRepurchaseMember2022-12-012022-12-310000927653mck:AcceleratedShareRepurchaseInitialShareSettlementMember2022-12-012022-12-310000927653mck:AcceleratedShareRepurchaseCompletionOfProgramMember2023-02-012023-02-280000927653mck:AcceleratedShareRepurchaseMember2022-05-012022-05-310000927653mck:AcceleratedShareRepurchaseMember2022-05-012022-08-310000927653mck:AcceleratedShareRepurchaseInitialShareSettlementMember2022-05-012022-05-310000927653mck:AcceleratedShareRepurchaseCompletionOfProgramMember2022-08-012022-08-310000927653mck:AcceleratedShareRepurchaseMember2022-02-012022-02-280000927653mck:AcceleratedShareRepurchaseMember2022-02-012022-05-310000927653mck:AcceleratedShareRepurchaseInitialShareSettlementMember2022-01-012022-03-310000927653mck:AcceleratedShareRepurchaseCompletionOfProgramMember2022-05-012022-05-3100009276532023-07-310000927653us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2023-09-300000927653mck:AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember2023-09-300000927653us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2023-09-300000927653us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember2023-09-300000927653us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2023-09-300000927653us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2023-10-012023-12-310000927653mck:AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember2023-10-012023-12-310000927653us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2023-10-012023-12-310000927653us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember2023-10-012023-12-310000927653us-gaap:AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember2023-10-012023-12-310000927653mck:AOCIAccumulatedGainLossNetInvestmentHedgesNoncontrollingInterestMember2023-10-012023-12-310000927653us-gaap:AccumulatedGainLossNetCashFlowHedgeNoncontrollingInterestMember2023-10-012023-12-310000927653us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossAttributableToNoncontrollingInterestMember2023-10-012023-12-310000927653us-gaap:AccumulatedTranslationAdjustmentMember2023-10-012023-12-310000927653mck:AOCIAccumulatedGainLossNetInvestmentHedgesPortionAttributableToParentMember2023-10-012023-12-310000927653us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-10-012023-12-310000927653us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember2023-10-012023-12-310000927653us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2023-12-310000927653mck:AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember2023-12-310000927653us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2023-12-310000927653us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember2023-12-310000927653us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2023-12-310000927653us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2022-09-300000927653mck:AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember2022-09-300000927653us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2022-09-300000927653us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember2022-09-300000927653us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2022-09-300000927653us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2022-10-012022-12-310000927653mck:AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember2022-10-012022-12-310000927653us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2022-10-012022-12-310000927653us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember2022-10-012022-12-310000927653us-gaap:AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember2022-10-012022-12-310000927653mck:AOCIAccumulatedGainLossNetInvestmentHedgesNoncontrollingInterestMember2022-10-012022-12-310000927653us-gaap:AccumulatedGainLossNetCashFlowHedgeNoncontrollingInterestMember2022-10-012022-12-310000927653us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossAttributableToNoncontrollingInterestMember2022-10-012022-12-310000927653us-gaap:AccumulatedTranslationAdjustmentMember2022-10-012022-12-310000927653mck:AOCIAccumulatedGainLossNetInvestmentHedgesPortionAttributableToParentMember2022-10-012022-12-310000927653us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-10-012022-12-310000927653us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember2022-10-012022-12-310000927653us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2022-12-310000927653mck:AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember2022-12-310000927653us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2022-12-310000927653us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember2022-12-310000927653us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2022-12-310000927653us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2023-03-310000927653mck:AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember2023-03-310000927653us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2023-03-310000927653us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember2023-03-310000927653us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2023-03-310000927653us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2023-04-012023-12-310000927653mck:AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember2023-04-012023-12-310000927653us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2023-04-012023-12-310000927653us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember2023-04-012023-12-310000927653us-gaap:AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember2023-04-012023-12-310000927653mck:AOCIAccumulatedGainLossNetInvestmentHedgesNoncontrollingInterestMember2023-04-012023-12-310000927653us-gaap:AccumulatedGainLossNetCashFlowHedgeNoncontrollingInterestMember2023-04-012023-12-310000927653us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossAttributableToNoncontrollingInterestMember2023-04-012023-12-310000927653us-gaap:AccumulatedTranslationAdjustmentMember2023-04-012023-12-310000927653mck:AOCIAccumulatedGainLossNetInvestmentHedgesPortionAttributableToParentMember2023-04-012023-12-310000927653us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-04-012023-12-310000927653us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember2023-04-012023-12-310000927653us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2022-03-310000927653mck:AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember2022-03-310000927653us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2022-03-310000927653us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember2022-03-310000927653us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2022-03-310000927653us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2022-04-012022-12-310000927653mck:AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember2022-04-012022-12-310000927653us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2022-04-012022-12-310000927653us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember2022-04-012022-12-310000927653us-gaap:AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember2022-04-012022-12-310000927653mck:AOCIAccumulatedGainLossNetInvestmentHedgesNoncontrollingInterestMember2022-04-012022-12-310000927653us-gaap:AccumulatedGainLossNetCashFlowHedgeNoncontrollingInterestMember2022-04-012022-12-310000927653us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossAttributableToNoncontrollingInterestMember2022-04-012022-12-310000927653us-gaap:AccumulatedTranslationAdjustmentMember2022-04-012022-12-310000927653mck:AOCIAccumulatedGainLossNetInvestmentHedgesPortionAttributableToParentMember2022-04-012022-12-310000927653us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-04-012022-12-310000927653us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember2022-04-012022-12-310000927653us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMembermck:UKBusinessesDisposalGroupMember2023-04-012023-09-300000927653mck:USPharmaceuticalSegmentMember2022-10-012022-12-310000927653mck:USPharmaceuticalSegmentMember2022-04-012022-12-310000927653mck:PrescriptionTechnologySolutionsSegmentMember2022-10-012022-12-310000927653mck:PrescriptionTechnologySolutionsSegmentMember2022-04-012022-12-310000927653mck:MedicalSurgicalSolutionsSegmentMember2022-10-012022-12-310000927653mck:MedicalSurgicalSolutionsSegmentMember2022-04-012022-12-310000927653mck:InternationalSegmentMember2022-10-012022-12-310000927653mck:InternationalSegmentMember2022-04-012022-12-310000927653us-gaap:ProductConcentrationRiskMembermck:USPharmaceuticalSegmentMemberus-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember2023-10-012023-12-310000927653us-gaap:ProductConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMembermck:PrescriptionTechnologySolutionsSegmentMember2023-10-012023-12-310000927653us-gaap:ProductConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMembermck:MedicalSurgicalSolutionsSegmentMember2023-10-012023-12-310000927653us-gaap:ProductConcentrationRiskMembermck:InternationalSegmentMemberus-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember2023-10-012023-12-310000927653country:US2023-10-012023-12-310000927653mck:USPharmaceuticalSegmentMember2023-07-012023-09-300000927653us-gaap:OperatingSegmentsMembermck:USPharmaceuticalSegmentMember2022-07-012022-07-310000927653mck:RxTsSegmentMember2023-10-012023-12-310000927653mck:RxTsSegmentMember2023-04-012023-12-310000927653us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberus-gaap:OperatingSegmentsMembermck:EUBusinessesDisposalGroupMembermck:InternationalSegmentMember2022-10-012022-12-310000927653us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberus-gaap:OperatingSegmentsMembermck:EUBusinessesDisposalGroupMembermck:InternationalSegmentMember2022-04-012022-12-310000927653us-gaap:CorporateNonSegmentMemberus-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMembermck:EUBusinessesDisposalGroupMember2022-10-012022-12-310000927653us-gaap:CorporateNonSegmentMemberus-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMembermck:EUBusinessesDisposalGroupMember2022-04-012022-12-310000927653mck:TaxReceivableAgreementTRAMember2022-10-012022-12-310000927653mck:TaxReceivableAgreementTRAMember2022-04-012022-12-310000927653mck:LeAnnSmithMember2023-04-012023-12-310000927653mck:LeAnnSmithMember2023-10-012023-12-310000927653mck:LeAnnSmithMember2023-12-310000927653mck:ThomasRodgersMember2023-04-012023-12-310000927653mck:ThomasRodgersMember2023-10-012023-12-310000927653mck:ThomasRodgersMember2023-12-310000927653mck:BrittVitaloneMember2023-04-012023-12-310000927653mck:BrittVitaloneMember2023-10-012023-12-310000927653mck:BrittVitaloneMember2023-12-31
Table of Contents                                          
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended December 31, 2023
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from             to             
Commission File Number: 1-13252
mckessonlogoa01.jpg
McKESSON CORPORATION
(Exact name of registrant as specified in its charter)
Delaware94-3207296
(State or other jurisdiction
of incorporation or organization)
(I.R.S. Employer
Identification No.)
6555 State Hwy 161,
Irving, TX 75039
(Address of principal executive offices, including zip code)
(972) 446-4800
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
(Title of each class)(Trading Symbol)(Name of each exchange on which registered)
Common stock, $0.01 par valueMCKNew York Stock Exchange
1.500% Notes due 2025MCK25New York Stock Exchange
1.625% Notes due 2026MCK26New York Stock Exchange
3.125% Notes due 2029MCK29New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes      No  
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes      No  
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer Accelerated filer 
Non-accelerated filer Smaller reporting company 
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).  Yes      No  
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date. 131,408,286 shares of the issuer’s common stock were outstanding as of December 31, 2023.


Table of Contents
McKESSON CORPORATION

TABLE OF CONTENTS
ItemPage
1
2
3
4
1
1A
2
3
4
5
6


2

Table of Contents
McKESSON CORPORATION

PART I—FINANCIAL INFORMATION

Item 1.    Condensed Consolidated Financial Statements.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In millions, except per share amounts)
(Unaudited)
 
Three Months Ended December 31, Nine Months Ended December 31,
 2023202220232022
Revenues$80,898 $70,490 $232,596 $207,801 
Cost of sales(77,746)(67,316)(223,353)(198,509)
Gross profit3,152 3,174 9,243 9,292 
Selling, distribution, general, and administrative expenses(2,506)(1,903)(6,468)(5,812)
Claims and litigation charges, net 1 2 5 
Restructuring, impairment, and related charges, net(4)(31)(84)(84)
Total operating expenses(2,510)(1,933)(6,550)(5,891)
Operating income642 1,241 2,693 3,401 
Other income, net34 276 98 466 
Interest expense(64)(69)(172)(169)
Income from continuing operations before income taxes612 1,448 2,619 3,698 
Income tax benefit (expense)18 (329)(289)(799)
Income from continuing operations630 1,119 2,330 2,899 
Income (loss) from discontinued operations, net of tax 1  (3)
Net income630 1,120 2,330 2,896 
Net income attributable to noncontrolling interests(41)(41)(119)(123)
Net income attributable to McKesson Corporation$589 $1,079 $2,211 $2,773 
Earnings (loss) per common share attributable to McKesson Corporation
Diluted
Continuing operations
$4.42 $7.65 $16.39 $19.32 
Discontinued operations
 0.01  (0.02)
Total
$4.42 $7.66 $16.39 $19.30 
Basic
Continuing operations
$4.45 $7.70 $16.49 $19.48 
Discontinued operations
 0.01  (0.02)
Total
$4.45 $7.71 $16.49 $19.46 
Weighted-average common shares outstanding
Diluted133.3 141.0 134.9 143.7 
Basic132.5 139.9 134.0 142.5 

See Financial Notes
3

Table of Contents
McKESSON CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(In millions)
(Unaudited)
 
 Three Months Ended December 31, Nine Months Ended December 31,
 2023202220232022
Net income$630 $1,120 $2,330 $2,896 
Other comprehensive income, net of tax
Foreign currency translation adjustments
72 252 60 642 
       Unrealized gains (losses) on cash flow and other hedges5 (65)37 (29)
Changes in retirement-related benefit plans
(2)28 (4)66 
Other comprehensive income, net of tax75 215 93 679 
Comprehensive income705 1,335 2,423 3,575 
Comprehensive income attributable to noncontrolling interests(41)(41)(119)(167)
Comprehensive income attributable to McKesson Corporation$664 $1,294 $2,304 $3,408 

See Financial Notes
4

Table of Contents
McKESSON CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS
(In millions, except per share amounts)
(Unaudited)
December 31, 2023March 31, 2023
ASSETS
Current assets
Cash and cash equivalents$1,982 $4,678 
Receivables, net23,066 19,410 
Inventories, net22,020 19,691 
Prepaid expenses and other572 513 
Total current assets47,640 44,292 
Property, plant, and equipment, net2,201 2,177 
Operating lease right-of-use assets1,679 1,635 
Goodwill9,973 9,947 
Intangible assets, net2,097 2,277 
Other non-current assets2,922 1,992 
Total assets$66,512 $62,320 
LIABILITIES AND DEFICIT
Current liabilities
Drafts and accounts payable$46,699 $42,490 
Short-term borrowings218  
Current portion of long-term debt48 968 
Current portion of operating lease liabilities296 299 
Other accrued liabilities4,400 4,200 
Total current liabilities51,661 47,957 
Long-term debt5,625 4,626 
Long-term deferred tax liabilities978 1,387 
Long-term operating lease liabilities1,421 1,402 
Long-term litigation liabilities6,128 6,625 
Other non-current liabilities2,381 1,813 
McKesson Corporation stockholders’ deficit
Preferred stock, $0.01 par value, 100 shares authorized, no shares issued or outstanding
  
Common stock, $0.01 par value, 800 shares authorized, 278 and 277 shares issued at December 31, 2023 and March 31, 2023, respectively
3 3 
Additional paid-in capital7,962 7,747 
Retained earnings14,268 12,295 
Accumulated other comprehensive loss(812)(905)
Treasury shares, at cost, 147 and 141 shares at December 31, 2023 and March 31, 2023, respectively
(23,474)(20,997)
Total McKesson Corporation stockholders’ deficit(2,053)(1,857)
Noncontrolling interests371 367 
Total deficit(1,682)(1,490)
Total liabilities and deficit$66,512 $62,320 
See Financial Notes
5

Table of Contents
McKESSON CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT
(In millions, except per share amounts)
(Unaudited)

Three Months Ended December 31, 2023
Common StockAdditional Paid-in CapitalRetained EarningsAccumulated Other Comprehensive LossTreasuryNoncontrolling
Interests
Total
Deficit
SharesAmountCommon SharesAmount
Balance, September 30, 2023
278 $3 $7,899 $13,761 $(887)(145)$(22,604)$364 $(1,464)
Issuance of shares under employee plans, net of forfeitures — 21 — — — (2)— 19 
Share-based compensation— — 45 — — — — — 45 
Repurchase of common stock— — — — — (2)(868)— (868)
Net income— — — 589 — — — 41 630 
Other comprehensive income— — — — 75 — — — 75 
Cash dividends declared, $0.62 per common share
— — — (83)— — — — (83)
Payments to noncontrolling interests— — — — — — — (37)(37)
Other— — (3)1 — — — 3 1 
Balance, December 31, 2023
278 $3 $7,962 $14,268 $(812)(147)$(23,474)$371 $(1,682)


Three Months Ended December 31, 2022
Common StockAdditional Paid-in CapitalRetained EarningsAccumulated Other Comprehensive LossTreasuryNoncontrolling
Interests
Total
 Deficit
SharesAmountCommon SharesAmount
Balance, September 30, 2022
277 $3 $7,609 $10,579 $(1,114)(135)$(18,844)$518 $(1,249)
Issuance of shares under employee plans, net of forfeitures— — 16 — — — (3)— 13 
Share-based compensation— — 36 — — — — — 36 
Repurchase of common stock— — (146)— — (5)(1,830)— (1,976)
Net income— — — 1,079 — — — 41 1,120 
Other comprehensive income— — — — 215 — — — 215 
Cash dividends declared, $0.54 per common share
— — — (77)— — — — (77)
Payments to noncontrolling interests— — — — — — — (36)(36)
Reclassification of recurring compensation to other accrued liabilities— — — — — — — (1)(1)
Formation of SCRI Oncology, LLC— — 22 — — — — 225 247 
Derecognition of noncontrolling interests in McKesson Europe AG— — — — — — — (382)(382)
Other— — (1)1 — — — 1 1 
Balance, December 31, 2022
277 $3 $7,536 $11,582 $(899)(140)$(20,677)$366 $(2,089)
See Financial Notes
6

Table of Contents
McKESSON CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT
(In millions, except per share amounts)
(Unaudited)

Nine Months Ended December 31, 2023
Common StockAdditional Paid-in CapitalRetained EarningsAccumulated Other Comprehensive LossTreasuryNoncontrolling
Interests
Total
Deficit
SharesAmountCommon SharesAmount
Balance, March 31, 2023
277 $3 $7,747 $12,295 $(905)(141)$(20,997)$367 $(1,490)
Issuance of shares under employee plans, net of forfeitures1 — 75 — — — (96)— (21)
Share-based compensation— — 136 — — — — — 136 
Repurchase of common stock— — — — — (6)(2,381)— (2,381)
Net income— — — 2,211 — — — 119 2,330 
Other comprehensive income— — — — 93 — — — 93 
Cash dividends declared, $1.78 per common share
— — — (240)— — — — (240)
Payments to noncontrolling interests— — — — — — — (114)(114)
Other— — 4 2 — — — (1)5 
Balance, December 31, 2023
278 $3 $7,962 $14,268 $(812)(147)$(23,474)$371 $(1,682)


Nine Months Ended December 31, 2022
Common StockAdditional Paid-in CapitalRetained EarningsAccumulated Other Comprehensive LossTreasuryNoncontrolling
Interests
Total
Deficit
SharesAmountCommon SharesAmount
Balance, March 31, 2022
275 $2 $7,275 $9,030 $(1,534)(130)$(17,045)$480 $(1,792)
Issuance of shares under employee plans, net of forfeitures2 1 143 — — — (157)— (13)
Share-based compensation— — 122 — — — — — 122 
Repurchase of common stock— — (25)— — (10)(3,475)— (3,500)
Net income— — — 2,773 — — — 123 2,896 
Other comprehensive income— — — — 635 — — 44 679 
Cash dividends declared, $1.55 per common share
— — — (222)— — — — (222)
Payments to noncontrolling interests— — — — — — — (113)(113)
Reclassification of recurring compensation to other accrued liabilities— — — — — — — (5)(5)
Formation of SCRI Oncology, LLC— — 22 — — — — 225 247 
Derecognition of noncontrolling interests in McKesson Europe AG— — — — — — — (382)(382)
Other— — (1)1 — — — (6)(6)
Balance, December 31, 2022
277 $3 $7,536 $11,582 $(899)(140)$(20,677)$366 $(2,089)
See Financial Notes
7

Table of Contents
McKESSON CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In millions)
(Unaudited)
 Nine Months Ended December 31,
 20232022
OPERATING ACTIVITIES
Net income$2,330 $2,896 
Adjustments to reconcile to net cash provided by operating activities:
Depreciation191 185 
Amortization284 262 
Long-lived asset impairment charges28 13 
Deferred taxes(552)55 
Charges (credits) associated with last-in, first-out inventory method89 (31)
Non-cash operating lease expense186 183 
Gain from sales of businesses and investments(17)(215)
Provision for bad debts780 31 
Other non-cash items137 190 
Changes in assets and liabilities, net of acquisitions:
Receivables(4,298)(2,193)
Inventories(2,384)(2,190)
Drafts and accounts payable4,163 3,531 
Operating lease liabilities(247)(256)
Taxes(40)381 
Litigation liabilities(529)(1,021)
Other46 13 
Net cash provided by operating activities167 1,834 
INVESTING ACTIVITIES
Payments for property, plant, and equipment(243)(265)
Capitalized software expenditures(175)(111)
Acquisitions, net of cash, cash equivalents, and restricted cash acquired(6)(856)
Proceeds from sales of businesses and investments, net47 1,074 
Other(118)(140)
Net cash used in investing activities(495)(298)
FINANCING ACTIVITIES
Proceeds from short-term borrowings4,770 1,100 
Repayments of short-term borrowings(4,552)(483)
Proceeds from issuances of long-term debt991 499 
Repayments of long-term debt(280)(412)
Purchase of U.S. government obligations for the satisfaction and discharge of long-term debt(647) 
Common stock transactions:
Issuances75 143 
Share repurchases(2,347)(3,500)
Dividends paid(232)(216)
Other(152)(309)
Net cash used in financing activities(2,374)(3,178)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash6 15 
Change in cash, cash equivalents, and restricted cash classified as Assets held for sale 470 
Net decrease in cash, cash equivalents, and restricted cash(2,696)(1,157)
Cash, cash equivalents, and restricted cash at beginning of period4,679 3,935 
Cash, cash equivalents, and restricted cash at end of period1,983 2,778 
Less: Restricted cash at end of period included in Prepaid expenses and other
(1)(4)
Cash and cash equivalents at end of period
$1,982 $2,774 
See Financial Notes
8

Table of Contents
McKESSON CORPORATION
FINANCIAL NOTES
(UNAUDITED)

1.    Significant Accounting Policies
Nature of Operations: McKesson Corporation (“McKesson,” or the “Company,”) is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. McKesson partners with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products, and services to help make quality care more accessible and affordable. The Company reports its financial results in four reportable segments: U.S. Pharmaceutical, Prescription Technology Solutions (“RxTS”), Medical-Surgical Solutions, and International. Refer to Financial Note 12, “Segments of Business,” for additional information.
Basis of Presentation: The condensed consolidated financial statements and accompanying notes are prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“GAAP”) for interim financial reporting and the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) and therefore do not include all information and disclosures normally included in the annual consolidated financial statements.
The condensed consolidated financial statements of McKesson include the financial statements of all wholly-owned subsidiaries and majority-owned or controlled companies. For those consolidated subsidiaries where the Company’s ownership is less than 100%, the portion of the net income or loss allocable to the noncontrolling interests is reported as “Net income attributable to noncontrolling interests” in the Condensed Consolidated Statements of Operations. All significant intercompany balances and transactions have been eliminated in consolidation, including the intercompany portion of transactions with equity method investees.
Net income attributable to noncontrolling interests includes third-party equity interests in the Company’s consolidated entities, including ClarusONE Sourcing Services LLP, Vantage Oncology Holdings, LLC, and SCRI Oncology, LLC. Net income attributable to noncontrolling interests also included recurring compensation that the Company was obligated to pay to the noncontrolling shareholders of McKesson Europe AG (“McKesson Europe”) through the divestiture date. The Company’s noncontrolling interest in McKesson Europe was included in the divestiture of certain of the Company’s businesses in the European Union (“E.U.”) in October 2022, which is discussed further in Financial Note 2, “Business Acquisitions and Divestitures.”
The Company considers itself to control an entity if it is the majority owner of or has voting control over such entity. The Company also assesses control through means other than voting rights and determines which business entity is the primary beneficiary of the variable interest entity (“VIE”). The Company consolidates VIEs when it is determined that it is the primary beneficiary of the VIE. Investments in business entities in which the Company does not have control, but instead has the ability to exercise significant influence over operating and financial policies, are accounted for using the equity method.
Fiscal Period: The Company’s fiscal year begins on April 1 and ends on March 31. Unless otherwise noted, all references to a particular year shall mean the Company’s fiscal year.
Reclassifications: Certain prior period amounts have been reclassified to conform to the current year presentation.
Use of Estimates: The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of these financial statements and income and expenses during the reporting period. Actual amounts could differ from those estimated amounts. In the opinion of management, the unaudited condensed consolidated financial statements include all normal recurring adjustments necessary for a fair presentation of the results of operations, financial position, and cash flows of McKesson for the interim periods presented.
The results of operations for the three and nine months ended December 31, 2023 are not necessarily indicative of the results that may be anticipated for the entire year. These interim financial statements should be read in conjunction with the annual audited financial statements, accounting policies, and financial notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2023, previously filed with the SEC on May 9, 2023 (the “2023 Annual Report”).

9

Table of Contents
McKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)
On August 16, 2022, the U.S. government enacted the Inflation Reduction Act of 2022 (the “IRA”). Among other provisions, the IRA includes a 15% corporate minimum tax, a 1% excise tax on certain repurchases of an entity’s own common stock after December 31, 2022, and various drug pricing reforms. The Company does not anticipate that this legislation will have a material impact on its consolidated financial statements or related disclosures; however the Company continues to evaluate the impact of these legislative changes. Refer to Financial Note 11, “Stockholders' Deficit,” for further details regarding excise taxes incurred on the Company’s share repurchases during the three and nine months ended December 31, 2023.
Recently Adopted Accounting Pronouncements
There were no accounting standards adopted by the Company during the nine months ended December 31, 2023.
Recently Issued Accounting Pronouncements Not Yet Adopted
In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 improves the transparency of income tax disclosures by requiring, on an annual basis, consistent categories, and greater disaggregation of information in the rate reconciliation as well as income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for the Company for fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments in this update should be applied prospectively, however, retrospective application is permitted. The Company is currently evaluating the impact that this guidance will have on its disclosures.
In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07 expands reportable segment disclosures by requiring disclosure, on an annual and interim basis, of significant segment expenses that are regularly provided to the chief operating decision maker (“CODM”) and included within each reported measure of segment profit or loss as well as an amount and description of other segment items. ASU 2023-07 also requires interim disclosures of a reportable segment’s profit or loss and assets, disclosure of the title and position of the CODM, and an explanation of how the CODM uses the reported measure of segment profit or loss in assessing performance and allocating resources. ASU 2023-07 is effective for the Company for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments in this update are required to be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact that this guidance will have on its disclosures.
In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions, which clarifies the guidance when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of such equity security and requires additional disclosure requirements. ASU 2022-03 is effective for the Company for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted. The amendments in this update are required to be applied prospectively. The Company does not anticipate that this guidance will have a material impact on its consolidated financial statements or related disclosures.

10

Table of Contents
McKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)
2.    Business Acquisitions and Divestitures
Acquisitions
Rx Savings Solutions, LLC
On November 1, 2022, the Company completed its acquisition of 100% of the shares of Rx Savings Solutions, LLC (“RxSS”), a privately-owned company headquartered in Overland Park, Kansas, to further connect biopharma and payer services to patients. RxSS is a prescription price transparency and benefit insight company that offers affordability and adherence solutions to health plans and employers. The purchase consideration included a payment of $600 million in cash made upon closing and a maximum of $275 million of contingent consideration based on RxSS’ operational and financial performance through calendar year 2025. The payment made upon closing was funded from cash on hand. The financial results of RxSS are included in the Company’s RxTS segment as of the acquisition date. The transaction was accounted for as a business combination.
The Company recorded a liability for the contingent consideration at its fair value of $92 million as of the acquisition date. The fair value of the contingent consideration liability was estimated using a Monte Carlo simulation model, utilizing internal cash flow projections which are Level 3 inputs under Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurements and Disclosures. The contingent consideration liability will be remeasured to fair value at each reporting date until the liability is settled with changes in fair value being recognized within “Selling, distribution, general, and administrative expenses” in the Company’s Condensed Consolidated Statements of Operations. During the three and nine months ended December 31, 2023, the Company recognized fair value adjustment gains of $2 million and $78 million, respectively, which reduced its contingent consideration liability, based on the estimated amount and timing of projected operational and financial information and the probability of achievement of performance milestones. As of December 31, 2023 and March 31, 2023, the current portion of the contingent consideration liability of $14 million and $83 million, respectively, is included within “Other accrued liabilities” and as of March 31, 2023, the long-term portion of $9 million is included within “Other non-current liabilities” in the Company’s Condensed Consolidated Balance Sheets. Recognition of the initial fair value of this contingent consideration was a non-cash investing activity.
The purchase price allocation included acquired identifiable intangible assets of $229 million, primarily representing customer relationships and technology with a weighted average amortization period of 12 years, and goodwill of $463 million. Goodwill has been allocated to the Company’s RxTS segment, which reflects the expected future benefits from certain synergies and intangible assets that do not qualify for separate recognition. Goodwill attributable to the acquisition is deductible for tax purposes.
The following table summarizes the final purchase price allocation for this acquisition:
(In millions)Amounts Recognized as of Acquisition Date (Final)
Purchase consideration:
Cash$600 
Contingent consideration92 
Total purchase consideration$692 
Identifiable assets acquired and liabilities assumed:
Current assets$5 
Intangible assets229 
Other non-current assets3 
Current liabilities(8)
Total identifiable net assets229 
Goodwill463 
Net assets acquired$692 

11

Table of Contents
McKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)
SCRI Oncology, LLC
On October 31, 2022, the Company completed a transaction with HCA Healthcare, Inc. (“HCA”) to form SCRI Oncology, LLC (“SCRI Oncology”), an oncology research business combining McKesson’s U.S. Oncology Research (“USOR”) and HCA’s Sarah Cannon Research Institute (“SCRI”) based in Nashville, Tennessee, to advance cancer care and increase access to oncology clinical research. McKesson owns a 51% controlling interest in the combined business, and the financial results are consolidated by the Company and reported within its U.S. Pharmaceutical segment as of the acquisition date. Transaction consideration included the transfer of full ownership interest in USOR to the combined business and $166 million of net cash paid to HCA, which was funded from cash on hand. The transaction was accounted for as a business combination.
The purchase price allocation included acquired identifiable intangible assets of $177 million, primarily representing customer relationships as well as trademarks and trade names with a weighted average amortization period of 17 years, and goodwill of $113 million. Goodwill has been allocated to the Company’s U.S. Pharmaceutical segment, which reflects the expected future benefits from certain synergies and intangible assets that do not qualify for separate recognition. Goodwill attributable to the acquisition of $46 million is deductible for tax purposes. The Company recorded noncontrolling interest of $225 million as a component of equity, which includes HCA’s proportionate interest in the identifiable net assets of SCRI at fair value of $202 million and its proportionate interest in the contributed net assets of USOR at carrying value of $23 million. The difference between the fair value of the Company’s acquired interest in SCRI net assets and the $166 million of net cash paid to HCA was recognized as additional paid in capital, as well as the Company’s reduction in ownership interest in USOR net assets.
The following table summarizes the final purchase price allocation for this acquisition:
(In millions)Amounts Recognized as of Acquisition Date (Final)
Purchase consideration:
Cash$166 
Contribution of USOR46 
Total purchase consideration$212 
Identifiable assets acquired and liabilities assumed:
Receivables$224 
Property, plant, and equipment22 
Operating lease right-of-use assets31 
Intangible assets177 
Other non-current assets6 
Current liabilities(42)
Long-term operating lease liabilities(29)
Other non-current liabilities(43)
Total identifiable net assets346 
Noncontrolling interest(225)
Additional paid-in capital(22)
Goodwill113 
Net assets acquired$212 

12

Table of Contents
McKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)
The fair value of the acquired identifiable intangible assets from the acquisitions discussed above were determined by applying the income approach, using a discounted cash flow model in which cash flows anticipated over several periods are discounted to their present value using an appropriate rate that is commensurate with the risk inherent with the transaction. These inputs are considered Level 3 inputs under the fair value measurements and disclosure guidance. The Company’s fair value assessments of these acquisitions were finalized upon completion of the measurement period in the third quarter of fiscal 2024. There were no material changes to the purchase price allocations since the respective acquisition dates. Pro forma financial information has not been provided as these acquisitions did not have a material impact, individually, or in the aggregate, to the Company’s consolidated results of operations.
Divestitures
European Divestiture Activities
In July 2021, the Company announced its intention to exit its businesses in Europe. On October 31, 2022, the Company completed its previously announced transaction to sell certain of its businesses in the E.U. located in France, Italy, Ireland, Portugal, Belgium, and Slovenia, along with its German headquarters and wound-care business, part of a shared services center in Lithuania, and its ownership stake in a joint venture in the Netherlands (“E.U. disposal group”) to the PHOENIX Group. As part of the transaction, the Company received cash proceeds of $892 million and divested net assets of $1.3 billion, including cash of $319 million, derecognized the carrying value of its noncontrolling interest held by minority shareholders of McKesson Europe of $382 million, and released $153 million of net accumulated other comprehensive loss.
During the three and nine months ended December 31, 2022, the Company recorded net gains of $31 million and $66 million, respectively, to remeasure the E.U. disposal group to fair value less costs to sell which was recorded within “Selling, distribution, general, and administrative expenses” in the Condensed Consolidated Statements of Operations. The Company’s measurement of the fair value of the E.U. disposal group was based on the total consideration received by the Company as outlined in the transaction agreement. Certain components of the total consideration included fair value measurements that fall within Level 3 of the fair value hierarchy.
On April 6, 2022, the Company completed the previously announced sale of its retail and distribution businesses in the United Kingdom (“U.K. disposal group”) to Aurelius Elephant Limited for a purchase price of £110 million (or, approximately $144 million), including certain adjustments. As part of the transaction, the Company divested net assets of $615 million and released $731 million of accumulated other comprehensive loss, within the International segment, and the buyer assumed and repaid a note payable to the Company of $118 million.
At December 31, 2023 and March 31, 2023, the Company had no assets or liabilities related to these European divestiture activities that met the criteria for classification as held for sale. Subsequent to the divestiture activities discussed above, the Company’s European operations primarily consist of its retail and distribution businesses in Norway.
Other
For the periods presented, the Company also completed de minimis acquisitions and divestitures within its operating segments. Financial results for the Company’s business acquisitions have been included in its consolidated financial statements as of their respective acquisition dates. Purchase prices for business acquisitions have been allocated based on estimated fair values at the respective acquisition dates.

13

Table of Contents
McKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)
3.    Restructuring, Impairment, and Related Charges, Net
The Company recorded restructuring, impairment, and related charges, net of $4 million and $31 million for the three months ended December 31, 2023 and 2022, respectively, and $84 million for each of the nine months ended December 31, 2023 and 2022. These charges were included in “Restructuring, impairment, and related charges, net” in the Condensed Consolidated Statements of Operations.
Restructuring Initiatives
During the fourth quarter of fiscal 2023, the Company approved a broad set of initiatives to drive operational efficiencies and increase cost optimization efforts, with the intent of simplifying its infrastructure and realizing long-term sustainable growth. These initiatives include headcount reductions and the exit or downsizing of certain facilities. The Company anticipates total charges of approximately $125 million across its RxTS and U.S. Pharmaceutical segments as well as Corporate, consisting primarily of employee severance and other employee-related costs, facility and other exit-related costs, as well as long-lived asset impairments. Of this amount, $101 million of cumulative charges were recorded through December 31, 2023. For the three and nine months ended December 31, 2023, the Company recorded charges of $2 million and $41 million related to this program, respectively, which primarily includes real estate and other related asset impairments and facility costs within Corporate. This restructuring program is anticipated to be substantially complete by the end of fiscal 2024.
Restructuring, impairment, and related charges, net for the three months ended December 31, 2023 and 2022 consisted of the following:
Three Months Ended December 31, 2023
(In millions)U.S. Pharmaceutical
Prescription Technology Solutions (1)
Medical-Surgical Solutions
International
Corporate Total
Severance and employee-related costs, net $(6)$1 $ $ $(2)$(7)
Exit and other-related costs (2)
1 1 3  6 11 
Asset impairments and accelerated depreciation      
Total$(5)$2 $3 $ $4 $4 
(1)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company’s technology solutions.
(2)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred.
Three Months Ended December 31, 2022
(In millions)U.S. PharmaceuticalPrescription Technology SolutionsMedical-Surgical SolutionsInternational
Corporate
Total
Severance and employee-related costs, net $ $ $ $ $4 $4 
Exit and other-related costs (1)
1 1 1 7 15 25 
Asset impairments and accelerated depreciation1   1  2 
Total$2 $1 $1 $8 $19 $31 
(1)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred. Corporate includes costs for business transformation and optimization efforts related to the Company’s technology organization. The International segment includes costs related to the Company’s European divestitures.

14

Table of Contents
McKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)
Restructuring, impairment, and related charges, net, for the nine months ended December 31, 2023 and 2022 consisted of the following:
Nine Months Ended December 31, 2023
(In millions)U.S. Pharmaceutical
Prescription Technology Solutions (1)
Medical-Surgical Solutions
International
Corporate (1)
Total
Severance and employee-related costs, net $3 $1 $ $2 $(1)$5 
Exit and other-related costs (2)
3 6 9 9 24 51 
Asset impairments and accelerated depreciation   1 27 28 
Total$6 $7 $9 $12 $50 $84 
(1)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company’s technology solutions.
(2)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred.
Nine Months Ended December 31, 2022
(In millions)U.S. PharmaceuticalPrescription Technology SolutionsMedical-Surgical SolutionsInternational
Corporate
Total
Severance and employee-related costs, net $3 $ $ $2 $(2)$3 
Exit and other-related costs (1)
2 4 3 15 44 68 
Asset impairments and accelerated depreciation4 11  2 (4)13 
Total$9 $15 $3 $19 $38 $84 
(1)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred. Corporate includes costs for business transformation and optimization efforts related to the Company’s technology organization. The International segment includes costs related to the Company’s European divestitures.
The following table summarizes the activity related to the liabilities associated with the Company’s restructuring initiatives for the nine months ended December 31, 2023:
(In millions)U.S. PharmaceuticalPrescription Technology SolutionsMedical-Surgical SolutionsInternationalCorporateTotal
Balance, March 31, 2023 (1)
$15 $26 $3 $13 $35 $92 
Restructuring, impairment, and related charges, net6 7 9 12 50 84 
Non-cash charges   (1)(27)(28)
Cash payments(14)(28)(10)(4)(33)(89)
Other (2)
5   (10) (5)
Balance, December 31, 2023 (3)
$12 $5 $2 $10 $25 $54 
(1)As of March 31, 2023, the total reserve balance was $92 million, of which $66 million was recorded in “Other accrued liabilities” and $26 million was recorded in “Other non-current liabilities” in the Company’s Condensed Consolidated Balance Sheet.
(2)Other primarily includes cumulative translation adjustments and transfers to certain other liabilities.
(3)As of December 31, 2023, the total reserve balance was $54 million, of which $21 million was recorded in “Other accrued liabilities” and $33 million was recorded in “Other non-current liabilities” in the Company’s Condensed Consolidated Balance Sheet.

15

Table of Contents
McKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)
4.    Income Taxes
Income tax expense (benefit) related to continuing operations was as follows:
Three Months Ended December 31, Nine Months Ended December 31,
(Dollars in millions)2023202220232022
Income tax expense (benefit)$(18)$329 $289 $799 
Reported income tax rate(2.9)%22.7 %11.0 %21.6 %
Fluctuations in the Company’s reported income tax rates were primarily due to changes in the mix of earnings between various taxing jurisdictions and discrete items recognized in the quarters.
During the three months ended December 31, 2023, the Company recognized a net discrete tax benefit of $141 million primarily related to the release of a valuation allowance based on management’s reassessment of the amount of its deferred tax assets that are more likely than not to be realized. As of each reporting date, management considers new evidence, both positive and negative, that could affect its view of the future realization of deferred tax assets. As of December 31, 2023, management determined that there is sufficient positive evidence to conclude that it is more likely than not that additional deferred tax assets of $154 million will be realized and reduced the valuation allowance accordingly. During the nine months ended December 31, 2023, the Company repatriated certain intellectual property between McKesson wholly-owned legal entities that are based in different tax jurisdictions. The transferor entity of the intellectual property was not subject to income tax on this transaction. The recipient entity of the intellectual property is entitled to amortize the fair value of the assets for tax purposes. As a result of this repatriation, and in accordance with ASU 2016-16, Intra-Entity Transfers of Assets Other Than Inventory, a net discrete tax benefit of $147 million was recognized during the nine months ended December 31, 2023. During the nine months ended December 31, 2022, the Company recognized net discrete tax benefits primarily related to the tax impact of share-based compensation of $55 million.
As of December 31, 2023, the Company had $1.4 billion of unrecognized tax benefits, of which $1.3 billion would reduce income tax expense and the effective tax rate if recognized. During the next twelve months, the Company does not anticipate any material reduction in its unrecognized tax benefits based on the information currently available. However, this may change as the Company continues to have ongoing discussions with various taxing authorities throughout the year.
The Company files income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions, and various foreign jurisdictions. The Company is generally subject to audit by taxing authorities in various U.S. states and in foreign jurisdictions for fiscal years 2016 through the current fiscal year.
During the fourth quarter of fiscal 2023, the Internal Revenue Service (“IRS”) communicated proposed adjustments to taxable income reported in the Company’s fiscal 2018 and fiscal 2019 U.S. Federal Corporate Income Tax returns. The adjustments would increase the Company’s federal income tax liability in the range of $600 million to $700 million. The Company disagrees with the proposed adjustments and intends to pursue resolution through the administrative process with the IRS Independent Office of Appeals and, if necessary, through judicial remedies. During the first quarter of fiscal 2024, the Company filed a formal protest with the IRS. The Company does not anticipate a final resolution of these matters in the next twelve months. Although the final resolution of these matters is uncertain, the Company believes in the merits of its tax positions and believes that it has adequately reserved for any adjustments to the provision of income taxes that may ultimately result. However, if the IRS prevails in these matters, the assessed tax and interest could have a material adverse effect on the Company’s financial position, results of operations, and cash flows in future periods.

16

Table of Contents
McKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)
5.    Earnings (Loss) Per Common Share
Basic earnings (loss) per common share is computed by dividing net income by the weighted-average number of common shares outstanding during the reporting period. The computation of diluted earnings (loss) per common share is similar to that of basic earnings (loss) per common share, except that the former reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock. Potentially dilutive securities include outstanding stock options, restricted stock units, and performance-based restricted stock units. Less than one million of potentially dilutive securities for the three and nine months ended December 31, 2023 and 2022 were excluded from the computation of diluted earnings (loss) per common share as they were anti-dilutive.
The computations for basic and diluted earnings (loss) per common share were as follows:
Three Months Ended December 31, Nine Months Ended December 31,
(In millions, except per share amounts)2023202220232022
Income from continuing operations$630 $1,119 $2,330 $2,899 
Net income attributable to noncontrolling interests(41)(41)(119)(123)
Income from continuing operations attributable to McKesson Corporation589 1,078 2,211 2,776 
Income (loss) from discontinued operations, net of tax 1  (3)
Net income attributable to McKesson Corporation$589 $1,079 $2,211 $2,773 
Weighted-average common shares outstanding:
Basic132.5 139.9 134.0 142.5 
Effect of dilutive securities:
Stock options0.1 0.2 0.2 0.3 
Restricted stock units (1)
0.7 0.9 0.7 0.9 
Diluted